Jove
Visualize
Contact Us

Related Experiment Videos

Atazanavir (Reyataz)

    Project Inform Perspective
    |December 31, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Atazanavir, a protease inhibitor, gained FDA approval in June 2003. It joins other similar antiviral medications used in treatment regimens.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Pharmacology
    • Virology
    • Drug Development

    Background:

    • Atazanavir (Reyataz) is identified as a protease inhibitor.
    • The U.S. Food and Drug Administration (FDA) approved atazanavir in June 2003.

    Discussion:

    • Atazanavir belongs to a class of antiretroviral drugs known as protease inhibitors.
    • This drug class plays a crucial role in managing viral infections by inhibiting viral enzymes essential for replication.

    Key Insights:

    • The approval of atazanavir expanded therapeutic options for patients requiring protease inhibitor therapy.
    • Its introduction signifies advancements in the development of targeted antiviral treatments.

    Outlook:

    • Further research may explore atazanavir's efficacy in combination therapies.
    • Continued development in protease inhibitor class aims to improve treatment outcomes and reduce drug resistance.